

NAME: David Baker

TITLE: Professor

EDUCATION

1983	BSc Zoology	Bedford College University of London, UK
1987	PhD Immunology/Pathology	Hunterian Institute, University of London, UK

EMPLOYMENT HISTORY

1983-1987	Research Assistant	Royal College of Surgeons of England, London
1987-1994	Lecturer	Hunterian Institute, RCS, London
1994-2000	Senior Lecturer	UCL Institute of Ophthalmology, London
1999-2004	Senior Lecturer	UCL Institute of Neurology, London
2004-2006	Professor	UCL Institute of Neurology, London
2006-present	Professor	Queen Mary University of London

WEBSITE: www.ms-res.org

RECENT PUBLICATIONS

<http://www.researchpublications.qmul.ac.uk/publications/staff/22180.html>

Baker D, Pryce G, Herrod SS, Schmierer K. Potential mechanisms of action related to the efficacy and safety of cladribine. *Mult Scler Relat Disord.* 2019;30:176-186.

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Champion T, Adams A, Turner BP, Marta M, Gnanapavan S, Espasandin M, Mathews J, Giovannoni G, Baker D, Schmierer K. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. *Mult Scler Relat Disord.* 2019;27:247-253.

Baker D, Pryce G, Amor S, Giovannoni G, Schmierer K. Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. *Brain.* 2018;141:2834-2847

Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K. Axonal loss in the multiple sclerosis spinal cord revisited. *Brain Pathol.* 2018;28:334-348.

Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ, Giovannoni G, Schmierer K. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. *J Neurol.* 2018;265:1199-1209.

Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K. Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. *Ann Clin Transl Neurol.* 2017;4:506-511.

Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K. Disease modification in advanced MS: Focus on upper limb function. *Mult Scler.* 2017; 23:1956-1957.

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. *Neurol Neuroimmunol Neuroinflamm.* 2017; 4:e360.

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.